You searched for baricitinib - Page 4 of 17

Abstract Number: 1990 • ACR Convergence 2020
Janus Kinase (JAK) Inhibition with Baricitinib in Refractory Juvenile Dermatomyositis
Hanna Kim¹, Lylan Bergeron², Samantha Dill², Michelle O'Brien², Laura Vian³, Minal Jain⁴, Manuk Manukyan², Xiaobai Li⁵, Shajia Lu³, Wanxia L. Tsai³, Kalyani Mishra Thakur⁶, Yinghui Shi⁶, Massimo Gadina⁷, April Brundidge², Michelle Millwood², Lisa G. Rider⁸ and Robert Colbert², ¹Juvenile Myositis Pathogenesis and Therapeutics Unit / NIAMS / National Institutes of Health, Bethesda, MD, ²Pediatric Clinical Trials Unit and Office of Clinical Director, NIAMS, NIH, Bethesda, MD, ³Translational Immunology Section, NIAMS, NIH, Bethesda, MD, ⁴Rehabilitation Medicine Department, Physical Therapy Section, Clinical Research Center, NIH, Bethesda, MD, ⁵Biostatistics and Clinical Epidemiology Service, Clinical Center, NIH, Bethesda, MD, ⁶Office of Clinical Director, NIAMS, NIH, Bethesda, MD, ⁷National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), NIH, Bethesda, MD, ⁸Environmental Autoimmunity Group, Clinical Research Branch, NIEHS, NIH, Garrett Park, MD
Background/Purpose: Juvenile dermatomyositis (JDM) is a systemic autoimmune disease with a prominent interferon (IFN) signature. Treatment often requires prolonged high-dose steroids and other immunosuppressive medications.…
Abstract Number: 313 • 2019 ACR/ARP Annual Meeting
Screening and Treating Hyperlipidemia in Patient’s on Tofacitinib, Tocilizumab, Sarilumab, and Baricitinib
William Torelli¹, James Ross ², Thomas Quinn ², Kourtney Erickson ¹, Andrea Soliman ¹ and Attiya Harit ³, ¹Lehigh Valley Health Network, Allentown, PA, ²lehigh valley health network, allentown, ³lehigh valley health organization, allentown
Background/Purpose: Background/Purpose: Tofacitinib and baricitinib (JAK inhibitors) are agents used for rheumatoid arthritis (RA), seronegative spondyloarthropathy (SpA), and juvenile idiopathic arthritis (JIA). Tocilizumab and sarilumab…
Abstract Number: 390 • 2019 ACR/ARP Annual Meeting
Preliminary Response to Janus Kinase (JAK) Inhibition with Baricitinib in Refractory Juvenile Dermatomyositis
Hanna Kim¹, Samantha Dill ², Michelle O'Brien ², Minal Jain ³, Shajia Lu ⁴, Wanxia Tsai ⁴, Yinghui Shi ⁵, Laura Vian ⁴, Massimo Gadina ⁴, Michelle Millwood ², April Brundidge ², Lisa G. Rider ⁶ and Robert Colbert ¹, ¹Pediatric Clinical Trials Unit, Pediatric Translational Research Branch, NIAMS, NIH, Bethesda, MD, ²Pediatric Clinical Trials Unit (PCTU), Office of the Clinical Director, NIAMS, NIH, Bethesda, MD, ³Rehabilitation Medicine Department, Physical Therapy Section, Clinical Research Center, NIH, Bethesda, MD, ⁴Translational Immunology Section, NIAMS, NIH, Bethesda, MD, ⁵Office of Clinical Director, NIAMS, NIH, Bethesda, MD, ⁶Environmental Autoimmunity Group, Clinical Research Branch, NIEHS, NIH, Bethesda, MD
Background/Purpose: Juvenile dermatomyositis (JDM) is a systemic autoimmune disease with a prominent interferon (IFN) signature. Treatment often requires prolonged high-dose steroids and other immunosuppressive medications.…
Abstract Number: 847 • 2019 ACR/ARP Annual Meeting
Safety Profile of Baricitinib for the Treatment of Rheumatoid Arthritis up to 7 Years: An Updated Integrated Safety Analysis
Mark Genovese¹, Josef Smolen ², Tsutomu Takeuchi ³, Gerd Burmester ⁴, Dennis Brinker ⁵, Terence Rooney ⁵, Jinglin Zhong ⁶, Daojun Mo ⁵, Chadi Saifan ⁵, Anabela Cardoso ⁵, Maher Issa ⁵, Wen-Shuo Wu ⁵ and Kevin Winthrop ⁷, ¹Stanford University, Stanford, CA, ²Medical University of Vienna, Vienna, Austria, ³Keio University School of Medicine, Tokyo, Japan, ⁴Charité—University Medicine Berlin, Berlin, Germany, ⁵Eli Lilly and Company, Indianapolis, IN, ⁶IQVIA, Morrisville, NC, ⁷Oregon Health and Science University, Portland, OR
Background/Purpose: Baricitinib (bari), an oral, selective inhibitor of Janus kinase (JAK) 1 and 2, is used to treat moderately to severely active RA in adults.…
Abstract Number: 1039 • 2019 ACR/ARP Annual Meeting
Molecular Profiling Identifies Immunologic Subgroups and Informs Mechanism of Action of Baricitinib in SLE
Thomas Dörner¹, Yoshiya Tanaka ², Michelle Petri ³, Josef Smolen ⁴, Daniel Wallace ⁵, Ernst Dow ⁶, Damiano Fantini ⁶, Richard Higgs ⁶, Guilherme Rocha ⁶, Brenda Crowe ⁶, Robert Benschop ⁶, Adam Abel ⁶, Nicole Byers ⁶, Maria Silk ⁶, Stephanie de Bono ⁶ and Robert Hoffman ⁶, ¹Charite Universitätsmedizin Berlin and DRFZ, Berlin, Germany, ²University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Medical University of Vienna, Vienna, Austria, ⁵Cedars-Sinai Medical Center/University California at Los Angeles, Los Angeles, CA, ⁶Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Baricitinib is an oral selective Janus kinase (JAK) 1 and JAK2 inhibitor. In the Phase II, 24-week, randomized, placebo-controlled, double-blind study JAHH (NCT02708095), once-daily…
Abstract Number: 1350 • 2019 ACR/ARP Annual Meeting
Patient Disease Trajectories in Baricitinib-2 Mg-Treated Patients with Rheumatoid Arthritis and Inadequate Response to Biologic DMARDs
Mark Genovese¹, Michael Weinblatt ², Jianmin Wu ³, Bochao Jia ³, Amanda Quebe ³, Luna Sun ³, Yun-Fei Chen ³, Cameron Helt ³, A. Kirstin Bacani ³, Paulo Reis ³ and Janet Pope ⁴, ¹Stanford University, Stanford, CA, ²Brigham and Women's Hospital, Boston, MA, ³Eli Lilly and Company, Indianapolis, IN, ⁴Western University, London, ON, Canada
Background/Purpose: Baricitinib (BARI), a selective Janus kinase 1 and 2 inhibitor, is approved for the treatment of moderately-to-severely active RA in over 60 countries. In…
Abstract Number: 1407 • 2019 ACR/ARP Annual Meeting
Baricitinib Provides Better Pain Relief Across All Disease Activity Levels Compared with Placebo and Adalimumab in Rheumatoid Arthritis
Peter Taylor¹, Janet Pope ², Kei Ikeda ³, Xiang Zhang ⁴, Bochao Jia ⁴, Hong Zhang ⁵, Amanda Quebe ⁴, Yun-Fei Chen ⁴, Carol Gaich ⁴, Thorsten Holzkaemper ⁴, Anabela Cardoso ⁴ and Anthony Sebba ⁶, ¹University of Oxford, Oxford, United Kingdom, ²Western University, London, ON, Canada, ³Chiba University Hospital, Chiba, Japan, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵TechData Services, King of Prussia, PA, ⁶University of South Florida, Palm Harbor, FL
Background/Purpose: In Phase 3 trial, RA-BEAM, baricitinib (BARI), a JAK1/JAK2 inhibitor, was associated with significant clinical improvements vs. placebo (PBO) and adalimumab (ADA) in RA…
Abstract Number: 1439 • 2019 ACR/ARP Annual Meeting
Effect of Baricitinib on Functional Impairment in RA Patients with Moderate Disease Activity and an Inadequate Response to Conventional DMARDs
Bruce Kirkham¹, Elena Nikiphorou ², Pedro López-Romero ³, Ilias Kouris ³, Thorsten Holzkaemper ³, Liliana Zaremba-Pechmann ⁴, Inmaculada de la Torre ³ and Peter Taylor ⁵, ¹Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom, ²King's College London, London, United Kingdom, ³Eli Lilly and Company, Indianapolis, IN, ⁴HaaPACS GmbH, Schriesheim, Germany, ⁵University of Oxford, Oxford, United Kingdom
Background/Purpose: In RA, disease activity correlates with physical function1 and there is a link between joint damage and functional disability2. In many countries, RA patients…
Abstract Number: 1772 • 2019 ACR/ARP Annual Meeting
Chronotherapy Using Baricitinib Attenuates Collagen-induced Arthritis in Mice
Arisa Yaekura¹, Kanta Morii ², Yuto Oketani ³, Ikumi Okumura ², Kenta Kaneshiro ⁴, Kohsuke Yoshida ², Yoshiko Kawasaki ⁵, Nao Shibanuma ⁵, Yoshitada Sakai ⁶ and Akira Hashiramoto ², ¹Kobe University Graduate School of Health Sciences, Kawanishi, Hyogo, Japan, ²Kobe University Graduate School of Health Sciences, Kobe, Hyogo, Japan, ³Kobe University Graduate School of Health Sciences, Himeji, Hyogo, Japan, ⁴Kobe University Graduate School of Health Sciences, Osaka, Osaka, Japan, ⁵Kobe Kaisei Hospital, Kobe, Hyogo, Japan, ⁶Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan
Background/Purpose: Diurnal variations are observed in symptoms of rheumatoid arthritis (RA). Among them, “morning stiffness of joints” is closely reflects the daily medical condition of…
Abstract Number: 1880 • 2019 ACR/ARP Annual Meeting
Baricitinib 4 Mg and 2 Mg Once Daily Reduced Pain in Both Patients Who Were Opioid Users and Non-users in Active Rheumatoid Arthritis: A Post-hoc Analysis of Phase 3 Trials
Janet Pope¹, Yvonne Lee ², Jeffrey Curtis ³, Daojun Mo ⁴, Terence Rooney ⁴, Li Xie ⁴, Christina Dickson ⁴, Douglas Schlichting ⁴, Amanda Quebe ⁴, Anabela Cardoso ⁴, Lee Simon ⁵ and Peter Taylor ⁶, ¹Western University, London, ON, Canada, ²Northwestern University Feinberg School of Medicine, Chicago, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵SDG LLC, Cambridge, MA, ⁶University of Oxford, Oxford, United Kingdom
Background/Purpose: Opioid use in RA patients has increased over the past 2 decades in the US. Little is known about the combined effects of opioids…
Abstract Number: 2375 • 2019 ACR/ARP Annual Meeting
Safety of Baricitinib Under Clinical Settings in Patients with Rheumatoid Arthritis, Using Data from All-Case Post-marketing Surveillance and Spontaneous Reports
Hiroaki Matsuno ¹, Tatsuya Atsumi ², Shuji Takei ³, Naoto Tamura ⁴, Masayoshi Harigai ⁵, Takao Fujii ⁶, Shigeki Momohara ⁷, Yuko Takahashi ⁸, Nobuhiro Narii ⁸, Naoto Tsujimoto ⁸, Atsushi Nishikawa ⁸, Taeko Ishii⁸, Kazuhiko Yamamoto ⁹, Masataka Kuwana ¹⁰ and Michiaki Takagi ¹¹, ¹Matsuno Clinic for Rheumatic Diseases, Toyama, Japan, ²Hokkaido University, Sapporo, Japan, ³Kagoshima University, Kagoshima, Japan, ⁴Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ⁵Department of Rheumatology, Tokyo Women's Medical University School of Medicine, Shinjuku-ku, Tokyo, Japan, ⁶Wakayama Medical University, Wakayama, Japan, ⁷Hakkeikai Incorporated Medical Institution, Shizuoka, Japan, ⁸Eli Lilly Japan K.K., Kobe, Japan, ⁹Riken Center for Integrative Medical Sciences, Kanagawa, Japan, ¹⁰Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, Bunkyo-ku, Tokyo, Japan, ¹¹Yamagata University Faculty of Medicine, Yamagata-shi, Japan
Background/Purpose: Baricitinib (bari), is an oral, selective inhibitor of Janus kinase (JAK) 1/ and JAK 2, is used to treat moderately to severely active RA…
Abstract Number: 546 • 2018 ACR/ARHP Annual Meeting
Baricitinib: Early Vs. Delayed Start in Patients with Rheumatoid Arthritis
Peter C. Taylor¹, Yoshiya Tanaka², Anabela Cardoso³, Jinglin Zhong⁴, Yun-Fei Chen³, Jennifer Lynn Workman³, Liliana del Carmen Morales⁵ and Michael Schiff⁶, ¹Botnar Research Centre, Univ of Oxford, Oxford, United Kingdom, ²University of Occupational and Environmental Health, Kitakyushu, Japan, ³Eli Lilly and Company, Indianapolis, IN, ⁴IQVIA, Morrisville, NC, ⁵INStituto Reumatologica Strusberg, Cordoba, Argentina, ⁶University of Colorado, Greenwood Village, CO
Background/Purpose: Baricitinib (bari) is an oral JAK1/JAK2 inhibitor approved for the treatment of moderately to severely active RA in adults in over 40 countries including…
Abstract Number: 574 • 2018 ACR/ARHP Annual Meeting
Longitudinal Efficacy Analysis of Patients with Active Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic Dmards: Response Following Rescue from Baricitinib 2mg to 4mg Once-Daily
Roy Fleischmann¹, Mark C. Genovese², Anabela Cardoso³, Luna Sun³, Yun-Fei Chen³, Chad D. Walls³, Douglas E. Schlichting³, Tsutomu Takeuchi⁴, Maxime Dougados⁵, Josef S. Smolen⁶ and Jeffrey R. Curtis⁷, ¹Metroplex Clinical Research Center, University of Texas Southwestern Medical Center, Dallas, TX, ²Stanford University Medical Center, Palo Alto, CA, ³Eli Lilly and Company, Indianapolis, IN, ⁴Keio University School of Medicine, Tokyo, Japan, ⁵Paris Descartes University, Hôpital Cochin, Paris, France, ⁶Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, ⁷University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Baricitinib (bari), an oral selective Janus kinase 1/2 inhibitor, has shown clinical efficacy in patients (pts) with RA and an inadequate response to conventional…
Abstract Number: 599 • 2018 ACR/ARHP Annual Meeting
Comparative Effectiveness in Pain and HAQ-DI Improvement for Baricitinib Versus Adalimumab, Tocilizumab, and Tofacitinib Monotherapies in Csdmard-Naïve Rheumatoid Arthritis Patients: A Matching-Adjusted Indirect Comparison (MAIC)
Bruno Fautrel¹, Baojin Zhu², Peter C. Taylor³, Mart van de Laar⁴, Paul Emery⁵, Francesco de Leonardis², Carol L. Gaich², Claudia Nicolay², Zbigniew Kadziola², Inmaculada de la Torre⁶ and Roy Fleischmann⁷, ¹University Pierre et Marie Curie, Paris, France, ²Eli Lilly and Company, Indianapolis, IN, ³Botnar Research Centre, Univ of Oxford, Oxford, United Kingdom, ⁴Arthritis Centre Twente, University of Twente, Enschede, Netherlands, ⁵Leeds MSK Biomed/Chapel Allerton Hospital, Leeds, United Kingdom, ⁶Eli Lilly and Company, Madrid, Spain, ⁷Metroplex Clinical Research Center, University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: In Phase 3 trial (RA-BEGIN), baricitinib (BARI) monotherapy demonstrated superiority to MTX in pain reduction and HAQ-DI improvement in treatment of csDMARD-naïve active RA…
Abstract Number: 886 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety of Switching from Adalimumab to Baricitinib: Long-Term Data from Phase 3 Extension Study in Patients with Rheumatoid Arthritis
Michael E Weinblatt¹, Peter C. Taylor², Edward C. Keystone³, Robert A. Ortmann⁴, Maher Issa⁴, Li Xie⁴, Stephanie de Bono⁴ and Yoshiya Tanaka⁵, ¹Brigham and Women’s Hospital, Boston, MA, ²Botnar Research Centre, Univ of Oxford, Oxford, United Kingdom, ³Mount Sinai Hospital, Toronto, ON, Canada, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵University of Occupational and Environmental Health, Kitakyushu, Japan
Background/Purpose: Baricitinib (bari) is an oral JAK1/JAK2 inhibitor approved for the treatment of moderately to severely active RA in adults in over 40 countries, including…

Janus Kinase (JAK) Inhibition with Baricitinib in Refractory Juvenile Dermatomyositis

Screening and Treating Hyperlipidemia in Patient’s on Tofacitinib, Tocilizumab, Sarilumab, and Baricitinib

Preliminary Response to Janus Kinase (JAK) Inhibition with Baricitinib in Refractory Juvenile Dermatomyositis

Safety Profile of Baricitinib for the Treatment of Rheumatoid Arthritis up to 7 Years: An Updated Integrated Safety Analysis

Molecular Profiling Identifies Immunologic Subgroups and Informs Mechanism of Action of Baricitinib in SLE

Patient Disease Trajectories in Baricitinib-2 Mg-Treated Patients with Rheumatoid Arthritis and Inadequate Response to Biologic DMARDs

Baricitinib Provides Better Pain Relief Across All Disease Activity Levels Compared with Placebo and Adalimumab in Rheumatoid Arthritis

Effect of Baricitinib on Functional Impairment in RA Patients with Moderate Disease Activity and an Inadequate Response to Conventional DMARDs

Chronotherapy Using Baricitinib Attenuates Collagen-induced Arthritis in Mice

Baricitinib 4 Mg and 2 Mg Once Daily Reduced Pain in Both Patients Who Were Opioid Users and Non-users in Active Rheumatoid Arthritis: A Post-hoc Analysis of Phase 3 Trials

Safety of Baricitinib Under Clinical Settings in Patients with Rheumatoid Arthritis, Using Data from All-Case Post-marketing Surveillance and Spontaneous Reports

Baricitinib: Early Vs. Delayed Start in Patients with Rheumatoid Arthritis

Longitudinal Efficacy Analysis of Patients with Active Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic Dmards: Response Following Rescue from Baricitinib 2mg to 4mg Once-Daily

Comparative Effectiveness in Pain and HAQ-DI Improvement for Baricitinib Versus Adalimumab, Tocilizumab, and Tofacitinib Monotherapies in Csdmard-Naïve Rheumatoid Arthritis Patients: A Matching-Adjusted Indirect Comparison (MAIC)

Efficacy and Safety of Switching from Adalimumab to Baricitinib: Long-Term Data from Phase 3 Extension Study in Patients with Rheumatoid Arthritis

Simple Search Results